The Uppsala-based company receives an additional patent on the US market for their PCR-based product.
The patent is a kit-patent that protects against competing companies making copies of Biovicas product. The patent complements previous patent on the US market, which protects the method for the analyzis, making the protection even stronger.
The patent is valid until May 2031.
“It is important for Biovica to protect our unique technology. Hence, it is very positive that we now strengthen our patent protection on our most important market,” says Anders Rylander, CEO, Biovica.
Photo of Anders Rylander: Biovica